Attovia reports Phase 1b itch drug topline data, plans Phase 2 starts in 1H 2027

Attovia Therapeutics reported third quarter 2026 financial results and a corporate update on November 9, 2026, highlighting positive 12-week Phase 1b data for its IL-31 targeting therapy ATTO-1310 in patients with chronic pruritus and high-itch atopic dermatitis from a Phase 1b trial, announced following a single dose of ATTO-1310 in patients with chronic pruritus and high-itch atopic dermatitis¹.

In the chronic pruritus population, 82% of ATTO-1310-treated patients achieved a four-point or greater reduction on the Peak Pruritus Numerical Rating Scale at week 12, compared with 22% on placebo, a nominally significant difference¹. In high-itch atopic dermatitis patients, 44% of treated patients achieved that same itch-relief threshold at week 4, versus 25% on placebo, with the response sustained through week 12¹. Skin improvements were also reported: 44% of ATTO-1310-treated patients reached at least a 75% improvement on the Eczema Area and Severity Index, and 39% achieved clear or almost clear skin on the validated Investigator Global Assessment, versus about 13% on placebo for both measures¹. The company said ATTO-1310 was generally well tolerated with low immunogenicity, and a single subcutaneous dose suppressed circulating IL-31 by about 95% through week 12, supporting potential quarterly dosing¹.

Attovia said it has advanced preparations for two Phase 2 ATTUNE trials in chronic pruritus of unknown origin and high-itch atopic dermatitis, with the CPUO trial design aligned with the FDA and site activation underway, and the AD trial protocol finalized with site selection initiated¹. Both are expected to begin in the first half of 2027, as is Phase 1 testing of two other pipeline candidates, ATTO-2306 and ATTO-1091 with Phase 1 trial initiation expected in the first half of 2027¹.

On financials, the company reported cash, cash equivalents, and marketable securities of $395.9 million as of September 30, 2026, up from $152.3 million at the end of 2025¹, which it said should be sufficient to fund operations into 2030¹.